Singapore markets close in 5 hours 30 minutes

Aprea Therapeutics, Inc. (APRE)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
5.35+0.07 (+1.33%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 29.05M
Enterprise value 265.00k
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.71
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.02

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 338.32%
S&P500 52-week change 322.38%
52-week high 38.85
52-week low 32.78
50-day moving average 36.32
200-day moving average 34.85

Share statistics

Avg vol (3-month) 331.5k
Avg vol (10-day) 36.51k
Shares outstanding 55.43M
Implied shares outstanding 65.53M
Float 84.19M
% held by insiders 111.67%
% held by institutions 117.69%
Shares short (15 Apr 2024) 496.18k
Short ratio (15 Apr 2024) 46.71
Short % of float (15 Apr 2024) 41.99%
Short % of shares outstanding (15 Apr 2024) 41.77%
Shares short (prior month 15 Mar 2024) 4117.11k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 313 Feb 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-26,109.62%

Management effectiveness

Return on assets (ttm)-36.63%
Return on equity (ttm)-63.19%

Income statement

Revenue (ttm)583.23k
Revenue per share (ttm)0.16
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -15.46M
Net income avi to common (ttm)-14.29M
Diluted EPS (ttm)-3.95
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)21.61M
Total cash per share (mrq)3.98
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)5.14
Book value per share (mrq)4.54

Cash flow statement

Operating cash flow (ttm)-12.18M
Levered free cash flow (ttm)-7.67M